The role of stress in the pathogenesis of Alzheimer’s disease
DOI:
https://doi.org/10.33910/2687-1270-2020-1-3-249-252Keywords:
Alzheimer’s disease, neurodegeneration, chronic stress, hypothalamicpituitary-adrenocortical axis (HPA axis), cortisol, glucocorticoid hormonesAbstract
Alzheimer’s disease is a multi-factorial neurodegenerative disease. Its diagnosis, especially in vivo, is often difficult, and the mechanisms of its development are still not clear. However, some markers were found, the most significant of which is the excessive deposition of abnormally folded proteins — beta-amyloid plaques and hyperphosphorylated neurofibrillar tangles of Tau protein. The exact causes of these and other markers are not known, but it has been established that factors of various nature, both exogenous and endogenous, can contribute to their manifestation. Indeed, the risk of this pathology increases significantly due to genetic predispositions since there are several genes whose mutations are associated with Alzheimer’s disease. Environmental factors, improper lifestyle and accompanying diseases, including metabolic disorders, also contribute to the development of this pathology. Another important factor is a chronic stress which has a negative impact on various body systems including the nervous system. This review summarizes the contribution of chronic stress to the pathogenesis of Alzheimer’s disease.
References
Ballard, C., Gauthier, S., Corbett, A. et al. (2011) Alzheimer’s disease. Lancet, vol. 377, no. 9770, pp. 1019–1031. PMID: 21371747. DOI: 10.1016/S0140-6736(10)61349-9 (In English)
Braak, H., Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica, vol. 82, no. 4, pp. 239–259. PMID: 1759558. DOI: 10.1007/BF00308809 (In English)
Budas, G., Coughlan, C. M., Seckl, J. R., Breen, K. C. (1999) The effect of corticosteroids on amyloid β precursor protein/amyloid precursor-like protein expression and processing in vivo. Neuroscience Letters, vol. 276, no. 1, pp. 61–64. PMID: 10586975. DOI: 10.1016/s0304-3940(99)00790-9 (In English)
Campbell, S. N., Zhang, C., Monte, L. et al. (2015a) Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor. Journal of Alzheimer’s Disease, vol. 43, no. 3, pp. 967–976. PMID: 25125464. DOI: 10.3233/JAD-141281 (In English)
Campbell, S. N., Zhang, C., Roe, A. D. et al. (2015b) Impact of CRFR1 ablation on amyloid-β production and accumulation in a mouse model of Alzheimer’s disease. Journal of Alzheimer’s Disease, vol. 45, no. 4, pp. 1175–1184. PMID: 25697705. DOI: 10.3233/jad-142844 (In English)
Canet, G., Hernandez, C., Zussy, C. et al. (2019) Is AD a stress-related disorder? Focus on the HPA axis and its promising therapeutic targets. Frontiers in Aging Neuroscience, vol. 11, article 269. PMID: 31611783. DOI: 10.3389/fnagi.2019.00269 (In English)
Caruso, A., Nicoletti, F., Gaetano, A., Scaccianoce, S. (2019) Risk factors for Alzheimer’s disease: Focus on stress. Frontiers in Pharmacology, vol. 10, article 976. PMID: 31551781. DOI: 10.3389/fphar.2019.00976 (In English)
de Quervain, D. J.-F., Poirier, R., Wollmer, M. A. et al. (2004) Glucocorticoid-related genetic susceptibility for Alzheimer’s disease. Human Molecular Genetics, vol. 13, no. 1, pp. 47–52. PMID: 14583441. DOI: 10.1093/hmg/ddg361 (In English)
Dong, H., Murphy, K. M., Meng, L. et al. (2012) Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer’s disease. Journal of Alzheimer’s Disease, vol. 28, no. 3, pp. 579–592. PMID: 22045495. DOI: 10.3233/JAD-2011-111328 (In English)
Elliott, E. M., Mattson, M. P., Vanderklish, P. et al. (1993) Corticosterone exacerbates kainate-induced alterations in hippocampal tau immunoreactivity and spectrin proteolysis in vivo. Journal of Neurochemistry, vol. 61, no. 1, pp. 57–67. PMID: 8515288. DOI: 10.1111/j.1471-4159.1993.tb03537.x (In English)
Filipcik, P., Novak, P., Mravec, B. et al. (2012) Tau protein phosphorylation in diverse brain areas of normal and CRH deficient mice: Up-regulation by stress. Cellular and Molecular Neurobiology, vol. 32, no. 5, pp. 837–845. PMID: 22222439. DOI: 10.1007/s10571-011-9788-9 (In English)
Gotz, J., Bodea, L.-G., Goedert, M. (2018) Rodent models for Alzheimer disease. Nature Reviews. Neuroscience, vol. 19, no. 10, pp. 583–598. PMID: 30194347. DOI: 10.1038/s41583-018-0054-8 (In English)
Green, K. N., Billings, L. M., Roozendaal, B. et al. (2006) Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer’s disease. The Journal of Neuroscience, vol. 26, no. 35, pp. 9047–9056. PMID: 16943563. DOI: 10.1523/JNEUROSCI.2797-06.2006 (In English)
Iqbal, K., Liu, F., Gong, C.-X., Grundke-Iqbal, I. (2010) Tau in Alzheimer disease and related tauopathies. Current Alzheimer Research, vol. 7, no. 8, pp. 656–664. PMID: 20678074. DOI: 10.2174/156720510793611592 (In English)
Kang, J.-E., Cirrito, J. R., Dong, H. et al. (2007) Acute stress increases interstitial fluid amyloid-β via corticotropinreleasing factor and neuronal activity. Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 25, pp. 10673–10678. PMID: 17551018. DOI: 10.1073/pnas.0700148104 (In English)
Marcus, C., Mena, E., Subramaniam, R. M. (2014) Brain PET in the diagnosis of Alzheimer’s disease. Clinical Nuclear Medicine, vol. 39, no. 10, pp. e413–e426. PMID: 25199063. DOI: 10.1097/RLU.0000000000000547 (In English)
McEwen, B. S. (2008) Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. European Journal of Pharmacology, vol. 583, no. 2–3, pp. 174–185. PMID: 18282566. DOI: 10.1016/j.ejphar.2007.11.071 (In English)
Rissman, R. A., Lee, K.-F., Vale, W., Sawchenko, P. E. (2007) Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. The Journal of Neuroscience, vol. 27, no. 24, pp. 6552–6562. PMID: 17567816. DOI: 10.1523/JNEUROSCI.5173-06.2007 (In English)
Shree, S., Bhardwaj, R., Deshmukh, K., Deshmukh, R. (2017) Non-transgenic animal models of Alzheimer’s disease. In: P. K. Bansal, R. Deshmukh (eds.). Animal models of neurological disorders: Principle and working procedure for animal models of neurological disorders. Singapore: Springer, pp. 3–22. DOI: 10.1007/978-981-10-5981-0_2 (In English)
Sooy, K., Noble, J., McBride, A. et al. (2015) Cognitive and disease-modifying effects of 11β-hydroxysteroid dehydrogenase type 1 inhibition in male Tg2576 mice, a model of Alzheimer’s disease. Endocrinology, vol. 156, no. 12, pp. 4592–4603. PMID: 26305888. DOI: 10.1210/en.2015-1395 (In English)
Sooy, K., Webster, S. P., Noble, J. et al. (2010) Partial deficiency or short-term inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice. The Journal of Neuroscience, vol. 30, no. 41, pp. 13867–13872. PMID: 20943927. DOI: 10.1523/JNEUROSCI.2783-10.2010 (In English)
Tasker, J. G., Herman, J. P. (2011) Mechanisms of rapid glucocorticoid feedback inhibition of the hypothalamicpituitary-adrenal axis. Stress, vol. 14, no. 4, pp. 398–406. PMID: 21663538. DOI: 10.3109/10253890.2011.586446 (In English)
Vaz-Silva, J., Gomes, P., Jin, Q. et al. (2018) Endolysosomal degradation of Tau and its role in glucocorticoid-driven hippocampal malfunction. The EMBO Journal, vol. 37, no. 20, article e99084. PMID: 30166454. DOI: 10.15252/embj.201899084 (In English)
Vyas, A., Pillai, A. G., Chattarji, S. (2004) Recovery after chronic stress fails to reverse amygdaloid neuronal hypertrophy and enhanced anxiety-like behavior. Neuroscience, vol. 128, no. 4, pp. 667–673. PMID: 15464275. DOI: 10.1016/j.neuroscience.2004.07.013 (In English)
Yau, J. L. W., Wheelan, N., Noble, J. et al. (2015) Intrahippocampal glucocorticoids generated by 11β-HSD1 affect memory in aged mice. Neurobiology of Aging, vol. 36, no. 1, pp. 334–343. PMID: 25109766. DOI: 10.1016/j.neurobiolaging.2014.07.007 (In English)
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Polina M. Shulga
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The work is provided under the terms of the Public Offer and of Creative Commons public license Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows an unlimited number of persons to reproduce and share the Licensed Material in all media and formats. Any use of the Licensed Material shall contain an identification of its Creator(s) and must be for non-commercial purposes only.
